Surgical management of primary malignant proximal fibular tumors: Functional and clinical outcomes of 23 patients
İsmail Burak Atalay1, Selçuk Yılmaz1, İzzet Korkmaz2, Mehmet Fatih Ekşioğlu1, Bedii Şafak Güngör1
01Department of Orthopedics and Traumatology, University of Health Sciences,
Dr. Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
2Department of Orthopedics and Traumatology, University of Health Sciences, Atatürk Training and Research Hospital, Ankara, Turkey
Keywords: Bone tumor, proximal fibula, tumor resection.
Objectives: This study aims to evaluate the clinical characteristics and treatment outcomes of patients with primary malignant tumors located in the proximal fibula.
Patients and methods: This retrospective study included 23 patients (15 males, 8 females; mean age 22.1 years; range, 9 to 63 years) with primary malignant tumors located in the proximal fibula between May 2007 and May 2017. The anamnesis or medical history, physical examination, plain chest radiography, lung computed tomography, direct radiograph, and magnetic resonance imaging of the affected extremity and routine laboratory tests of all patients were evaluated.
Results: Of the patients, 11 were diagnosed with osteosarcoma (47.8%), nine with Ewing’s sarcoma (39.1%), two with chondrosarcoma (8.7%), and one was diagnosed with synovial sarcoma (4.3%). Pain and palpable mass were the most common symptoms. Six patients had lung metastases at the time of diagnosis. Of the patients, eight were performed Malawer type 1 resection (34.8%), nine type 2 resection (39.1%), four above knee amputation (17.4%), and two proximal tibia tumor resection prosthesis (8.6%). Mean follow-up duration was 36 months (range, 12 to 119 months). Local recurrence developed in three patients. Mean Musculoskeletal Tumor Society (MSTS) score of all patients was 62.
Conclusion: Surgical treatment of primary malignant tumors of the proximal fibula is problematic. In appropriate indications, Malawer type 1 resection should be the treatment of choice due to lower local recurrence rates and higher MSTS scores.